Wednesday, February 10, 2010, 10:38AM AEST - The Australian Stockmarket closes in 5 hours and 27 minutes.
To create a watchlist or portfolio of shares, Register

Alkermes, Inc. (ALKS)

8:00AM AEST: 11.43 USD  Up 0.06 (0.53%)  
 MORE ON ALKS 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Alkermes, Inc. (NasdaqNM:ALKS) Delayed quote dataEdit
Last Trade:11.43 USD
Trade Time: 8:00AM AEST
Change:Up 0.06 (0.53%)
Prev Close:11.37
Open:11.60
Bid:11.25 x 200
Ask:11.94 x 100
1y Target Est:10.29
Day's Range:11.40 - 11.68
52wk Range:7.41 - 13.16
Volume:1,086,280
Avg Vol (3m):1,185,770
Market Cap:1.08B
P/E (ttm):13.57
EPS (ttm):0.84
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add ALKS to Portfolio   Download Data

 HEADLINES 
Alkermes Retains Neutral Rec
Zacks.com (Tue 7:07AM)
[video] Alkermes CEO Sounds Off
at CNBC (Tue 1:50AM)
New Star Analyst Rankings for Alkermes, Inc.
StarMine (Sun, Feb 7)
[$$] Russell 2000 Falls for Fourth Week in a Row
at The Wall Street Journal Online (Sat, Feb 6)
Biotech Stocks: Drug stocks fall; Alkermes rallies on upgrade
at MarketWatch (Sat, Feb 6)
Biotech Stocks: Drug stocks slip; Alkermes rallies on upgrade
at MarketWatch (Sat, Feb 6)
Lower Q3 Loss for Alkermes
Zacks.com (Sat, Feb 6)
Drug stocks dip; Alkermes jumps on upgrade
at MarketWatch (Sat, Feb 6)
Premarket roundup: PerkinElmer, NCR
AP (Sat, Feb 6)
Ahead of the Bell: Alkermes upgraded on 3Q results
AP (Sat, Feb 6)
Wall Street Breakfast: Must-Know News
at Seeking Alpha (Fri, Feb 5)
Alkermes upgraded by Jefferies & Co
Briefing.com (Fri, Feb 5)
Alkermes, Inc. F3Q10 (Qtr End 12/31/09) Earnings Call Transcript
at Seeking Alpha (Fri, Feb 5)
More Headlines for ALKS...

 ANALYST 
EPS Est (next year) (Mar-10) :-0.53
EPS Est (in 2 years) (Mar-11) :-0.14
Avg Rec (current)*:2.7
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Alkermes, Inc., an integrated biotechnology company, offers extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction, and diabetes.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices